Abstract:OBJECTIVE:To assess the efficacy and pathological change of fertility-sparing treatment with progestin for endometrial carcinoma (EC) of stage I a and complex atypical hyperplasia (CAH) and to observe the prognosis of the treatment.METHODS:Nine EC patients of stage I a and 21 CAH patients aged under 40 years who desired childbearing and retaining their fertility were enrolled into this study. All patients were given a daily oral high-dose of progestin with duration of treatment ranging from 6 to 9 months. Diagnostic curettage was performed every 3 months as a modality for seeing the histologic change of neoplastic tissues and endometrial tissue. A careful and long- term follow- up is necessary for patients with complete response (CR).RESULTS:During the first period of fertility-sparing management, according to histologic change, 5 EC patients and 18 CAH patients showed CR with no evidence of endometrial adenocarcinoma or hyperplasia, 2 EC patients and 2 CAH patients showed partial response with a regression to complex or simple hyperplasia without atypia, 2 EC patients and 1 CAH patient showed stable disease or progressive disease. Accordingly, a total of 26 patients showed CR (26 of 30 patients). The median time to CR was 6 months (range, 3 to 21 months) of progestin treatment. The median follow-up time was 55.5 months (range, 24 to 104 months) and all patients were alive. During follow-up, among the 26 patients with CR, 3 of 6 EC patients achieved CR recurred disease after a median time interval of 10 months (range, 6 to 51 months), 7 of 20 CAH patients achieved CR had recurrent disease after a median time interval of 12 months (range, 6 to 55 months). Four of 7 CAH with recurrent disease achieved CR to progestin re-treatment. Eight of 26 patients achieved CR continued a further 3 or 6 months of consolidation therapy, 3 of them had recurrent disease, the remaining 18 stopped progesterone treatment after CR and 7 patients had recurrent disease; there was no significant statistical difference between the two groups (P = 1.000). EC patients succeeded in 4 pregnancies, CAH patients succeeded in 10 pregnancies, they gave birth to 16 healthy babies in all.CONCLUSIONS:EC of stage I a and CAH had slow progression of symptoms. Progestin treatment in EC of stage I a and CAH patients was effective. A careful and long-term follow-up is required because of the substantial high rate of recurrence. Progestin re-treatment in most patients with recurrent endometrial cancer is effective and safe.

Effects of Estrogen, Progestin and Mifepristone on Endometrial Carcinoma Cell Lines

Functional Study of Progesterone Receptor Isoforms in Endometrial Cancer Cell Lines

Treatment of Endometriosis with Mifepristone Mediated by Nanostructured Lipid Carriers

The Effect of Progesterone and Tamoxifen on Cell Proliferation and the Expression of Estrogen Receptor Related Receptor of Endometrial Carcinoma

The Role of Steroid Receptors in the Proliferation and Migration of Endometrial Adenocarcinoma HEC1A Cell Line

Estrogenic effects of two derivatives of icariin on human breast cancer MCF-7 cells

Hearing: Asking the auditory cortex the right question

Effects of Mifepristone on Proliferation of Human Gastric Adenocarcinoma Cell Line SGC-7901 in Vitro

INHIBITORY EFFECTS OF MIFEPRISTONE ON THE GROWTH OF HUMAN GASTRIC CANCER CELL LINE MKN-45 IN VITRO AND IN VIVO

Involvement of Cyclin B1 in Progesterone-Mediated Cell Growth Inhibition, G2/M Cell Cycle Arrest, and Apoptosis in Human Endometrial Cell

[Effects of ICI182780 (faslodex) on Proliferation and Apoptosis Induced by 17Beta-Estradiol in Endometrial Carcinoma Cells].

The Effect of IGF- 1 and Estrodial on Endometrial Carcinoma Cells HEC - 1A

The effect of estrogen and tamoxifen on the growth of endometrial carcinoma cell

[Effects of Pathological Assessment of Endometrial Tissue in Fertility-Sparing Treatment with Progestin for Endometrial Carcinoma of Stage I a and Complex Atypical Hyperplasia].

[Influence of Long-Term Treatment with MPA on the Biological Character of Endometrial Carcinoma Ishikawa Cell].

Regulation of IGFs Expression in Endometrial Carcinoma Cells by Estrogen and Progesterone

Effects of Mifepristone on the Growth and Metastasis of Human Gastric Cancer in Vivo and in Vitro

[Regulation of Human Progesterone Receptor Isoforms A and B in Uterine Endometrial Carcinoma by Estrogen and Insulin-Like Growth Factor-1].

[Effect of Gonadotropin-Releasing Hormone-I Agonist and Gonadotropin-Releasing Hormone-Ii on Endometrial Carcinoma Cell Lines with Different States of PTEN].

Effect of Progesterone on the Expression of HOXA11 Gene in Cultured Human Endometrial Glandular Epithelial Cells

The Effect of Mifepristone on the Expression of Insulin-Like Growth Factor Binding Protein-1, Prolactin and Progesterone Receptor Mrna and Protein During the Implantation Phase in Human Endometrium